Are androgen receptor agonists a treatment option in bladder cancer?
Files
(Published version)
Date
2024
Authors
De Ieso, M.L.
Aldoghachi, A.F.
Tilley, W.D.
Dwyer, A.R.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Journal of Steroid Biochemistry and Molecular Biology, 2024; 245:106623-1-106623-5
Statement of Responsibility
Michael L. De Ieso, Ahmed Faris Aldoghachi, Wayne D. Tilley, Amy R. Dwyer
Conference Name
Abstract
Sex-related differences in bladder cancer incidence and progression infer a role for sex hormones and their cognate receptors in this disease. In part due to the oncogenic role of androgen receptor signaling in prostate cancer, the focus of most preclinical and clinical research to-date has been on the potential pro-tumorigenic action of androgens in urothelial cancers. However, clinical studies of androgen receptor antagonism have yielded minimal success. In this review, we explore the tumor suppressor role of androgen receptor in bladder cancer and discuss how it might be harnessed therapeutically.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).